The COVID-19 Immunity Task Force funds comprehensive new SARS-CoV-2 seroprevalence study focused on aging Canadians
RI-MUHC researcher Christina Wolfson co-leads study investing in our most...
Supporting those grieving requires “literacy,” researcher Mary Ellen Macdonald suggests
Grief amidst the pandemic is an increasing reality in communities worldwide
Spike in peanut and nut anaphylaxis in children at Halloween and Easter
New study suggests education and awareness are needed to help reduce risk of anaphylaxis at specific times of the year
Sleep apnea treatment reduces heart problems in patients with prediabetes, a new study finds
People with prediabetes and obstructive sleep apnea could reduce their daytime resting heart rate and risk of cardiovascular disease by using a CPAP machine at night
Containment Level 3 facilities advance COVID-19 research at the RI-MUHC and McGill
Infrastructure to study COVID-19 in a secure environment is creating new possibilities for collaboration and discovery
From silent infection to rapid death: Why are some people more vulnerable to COVID-19?
Scientists discover genetic and immunological causes of 15 percent of life-threatening COVID-19 cases
15,000 COVID-19 tests produced by McGill University and the RI-MUHC: a step toward Canadian self-sufficiency
In July 2020, the McGill University Health Centre’s (MUHC's) Department of Clinical...
Protecting lung cancer patients from COVID-19 – and learning from the experience
A study led by Dr. Nathaniel Bourganim tracked changes in treatment plans
New study of therapy options in metastatic melanoma
RI-MUHC researchers lead “real-world” analysis of treatment patterns with checkpoint inhibitors
Nip it in the bud: New study will attack SARS-Cov2 where it multiplies
RI-MUHC researchers initiate a clinical trial of ciclesonide to possibly prevent mild cases of COVID-19 from worsening